EMA Decision Due For Minoryx’s Leriglitazone & Apellis’ Pegcetacoplan

 
• By Eliza Slawther

The European Medicines Agency is this week due to decide whether to back pan-EU marketing authorization for five new medicines, including a combination antibiotic product and a drug for chemotherapy-induced neutropenia.

Conference room interior with big table and screen
The EMA's Human medicines committee will meet this week to decide which drugs should be approved in the EU • Source: Shutterstock

More from Approvals

More from Product Reviews